{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:08:22Z","timestamp":1778742502130,"version":"3.51.4"},"reference-count":68,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Epilepsy Research Institute","award":["F2401"],"award-info":[{"award-number":["F2401"]}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"crossref","award":["SGL030\\1029"],"award-info":[{"award-number":["SGL030\\1029"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"crossref","award":["CL-2022-07-002"],"award-info":[{"award-number":["CL-2022-07-002"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2026,3,21]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metformin demonstrates antiepileptogenic (primary prevention) and antiseizure (symptom control) properties in animal models of epilepsy. It is unclear whether these effects translate to humans, particularly outside diabetes, where metformin is increasingly prescribed for weight loss for example. We therefore addressed two questions in people without evidence of diabetes: (1) following an incident brain insult (ischaemic stroke, intracranial haemorrhage, head injury or brain tumour), is metformin associated with reduced risk of first recorded seizure, epilepsy diagnosis or antiseizure medication (ASM) initiation? (2) In established epilepsy treated with ASMs, is metformin add-on associated with reduced risk of potentially seizure-related morbidity (coded seizures, emergency department attendances, hospital admissions, falls, injuries, burns or a composite of these) and all-cause mortality?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We undertook an international retrospective cohort study of real-world healthcare data in TriNetX. Propensity score matched cohorts compared metformin against licensed weight-management comparators. Cox proportional hazards models estimated HRs with 95% CIs for 10\u2009year outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>16\u2009695 participants were included. Following brain insult, metformin was not associated with reduced risk of first recorded seizure, epilepsy diagnosis or ASM initiation. In established epilepsy, metformin add-on was associated with significantly lower hazards of coded seizures (HR 0.778, CI 0.624 to 0.971), emergency attendance or hospital admission (HR 0.696, CI 0.569 to 0.851), falls\/injuries\/burns (HR 0.677, CI 0.510 to 0.898) and a composite of these events (HR 0.729, CI 0.626 to 0.848; approximate number needed to treat ~6 at 10 years). Mortality did not differ (HR 1.039, CI 0.594 to 1.816).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metformin could have repurposed benefits in epilepsy. This warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2025-337861","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:20:18Z","timestamp":1778692818000},"page":"jnnp-2025-337861","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of metformin for epilepsy prevention or seizure control in people without evidence of diabetes: retrospective cohort study"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9588-2944","authenticated-orcid":false,"given":"Gashirai K","family":"Mbizvo","sequence":"first","affiliation":[{"name":"Liverpool Interdisciplinary Neuroscience Centre, University of Liverpool, Liverpool, UK"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK"},{"name":"Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK"},{"name":"The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-2845","authenticated-orcid":false,"given":"Josephine","family":"Mayer","sequence":"additional","affiliation":[{"name":"Liverpool Interdisciplinary Neuroscience Centre, University of Liverpool, Liverpool, UK"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK"},{"name":"Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK"},{"name":"The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha Mary","family":"George","sequence":"additional","affiliation":[{"name":"Liverpool Interdisciplinary Neuroscience Centre, University of Liverpool, Liverpool, UK"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK"},{"name":"Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-9212","authenticated-orcid":false,"given":"Laura Jayne","family":"Bonnett","sequence":"additional","affiliation":[{"name":"Department of Health Data Science, Institute of Population Health, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen P","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Sperrin","sequence":"additional","affiliation":[{"name":"Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6398-2537","authenticated-orcid":false,"given":"Piet\u00e0 Georgina","family":"Schofield","sequence":"additional","affiliation":[{"name":"Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4396-5657","authenticated-orcid":false,"given":"William Owen","family":"Pickrell","sequence":"additional","affiliation":[{"name":"Swansea University Medical School, Singleton Park, Swansea, UK"},{"name":"Department of Neurology, Morriston Hospital, Swansea Bay University Health Board, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK"},{"name":"Diabetes & Endocrinology Research and Pain Research Institute, Institute of Life Course and Medical Sciences, University of Liverpool and Liverpool University Hospital NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasir","family":"Mirza","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3392-1650","authenticated-orcid":false,"given":"Iain Edward","family":"Buchan","sequence":"additional","affiliation":[{"name":"Department of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK"},{"name":"Danish Centre for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK"},{"name":"The Walton Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026051310201148000_jnnp-2025-337861v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32596-0"},{"key":"2026051310201148000_jnnp-2025-337861v1.2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/7854_2020_216","article-title":"Disease Modification in Epilepsy: Behavioural Accompaniments","volume":"55","author":"Russo","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"2026051310201148000_jnnp-2025-337861v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70310-0"},{"key":"2026051310201148000_jnnp-2025-337861v1.4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejpn.2019.12.005","article-title":"The concept of disease modification","volume":"24","author":"Cross","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"2026051310201148000_jnnp-2025-337861v1.5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196274","article-title":"The long-term outcomes of epilepsy surgery","volume":"13","author":"Mohan","year":"2018","journal-title":"PLoS ONE"},{"key":"2026051310201148000_jnnp-2025-337861v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2019-002192"},{"key":"2026051310201148000_jnnp-2025-337861v1.7","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000528"},{"key":"2026051310201148000_jnnp-2025-337861v1.8","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690030080013"},{"key":"2026051310201148000_jnnp-2025-337861v1.9","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.752814"},{"key":"2026051310201148000_jnnp-2025-337861v1.10","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1007\/s00210-024-03295-1","article-title":"Exploring the clinical connections between epilepsy and diabetes mellitus: Promising therapeutic strategies utilizing agmatine and metformin","volume":"397","author":"Nangia","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026051310201148000_jnnp-2025-337861v1.11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.seizure.2022.09.003","article-title":"A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis","volume":"101","author":"Singh","year":"2022","journal-title":"Seizure"},{"key":"2026051310201148000_jnnp-2025-337861v1.12","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17965"},{"key":"2026051310201148000_jnnp-2025-337861v1.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12062-w"},{"key":"2026051310201148000_jnnp-2025-337861v1.14","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-023-00718-2","article-title":"Genetic prediction of antihyperglycemic drug targets and risk of epilepsy: a mendelian randomisation study","volume":"25","author":"Zhou","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026051310201148000_jnnp-2025-337861v1.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100715","article-title":"The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial","volume":"32","author":"Amin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026051310201148000_jnnp-2025-337861v1.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1132-3","article-title":"Treatment with metformin in twelve patients with Lafora disease","volume":"14","author":"Bisulli","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2026051310201148000_jnnp-2025-337861v1.17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s13311-022-01304-w","article-title":"Early Treatment with Metformin Improves Neurological Outcomes in Lafora Disease","volume":"20","author":"Burgos","year":"2023","journal-title":"Neurotherapeutics"},{"key":"2026051310201148000_jnnp-2025-337861v1.18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00228-018-2593-3","article-title":"Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis","volume":"75","author":"Hui","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2026051310201148000_jnnp-2025-337861v1.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207947","article-title":"Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis","volume":"13","author":"Solym\u00e1r","year":"2018","journal-title":"PLoS ONE"},{"key":"2026051310201148000_jnnp-2025-337861v1.20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fendo.2020.00191","article-title":"Metformin and Its Benefits for Various Diseases","volume":"11","author":"Lv","year":"2020","journal-title":"Front Endocrinol"},{"key":"2026051310201148000_jnnp-2025-337861v1.21","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3390\/ijms19102863","article-title":"Metformin: An Old Drug with New Applications","volume":"19","author":"Zhou","year":"2018","journal-title":"IJMS"},{"key":"2026051310201148000_jnnp-2025-337861v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2007.05.009"},{"key":"2026051310201148000_jnnp-2025-337861v1.23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.0b013e3181ab2b11","article-title":"Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy","volume":"73","author":"Daniels","year":"2009","journal-title":"Neurology (ECronicon)"},{"key":"2026051310201148000_jnnp-2025-337861v1.24","doi-asserted-by":"crossref","unstructured":"Zhu T , Long Z , Zhu S , et al . Elevated body roundness index and epilepsy prevalence: a cross-sectional study. Sci Rep 2026;16. doi:10.1038\/s41598-026-36062-8","DOI":"10.1038\/s41598-026-36062-8"},{"key":"2026051310201148000_jnnp-2025-337861v1.25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/08830738231203761","article-title":"Socioecologic Factors Associated With Obesity in Adolescents With Epilepsy in the United States","volume":"38","author":"Buro","year":"2023","journal-title":"J Child Neurol"},{"key":"2026051310201148000_jnnp-2025-337861v1.26","doi-asserted-by":"crossref","first-page":"110735","DOI":"10.1016\/j.yebeh.2025.110735","article-title":"High prevalence of obesity and reduced physical activity among people with epilepsy: A single-centre cross-sectional study","volume":"172","author":"Chang","year":"2025","journal-title":"Epilepsy Behav"},{"key":"2026051310201148000_jnnp-2025-337861v1.27","doi-asserted-by":"crossref","first-page":"110295","DOI":"10.1016\/j.yebeh.2025.110295","article-title":"Investigation of the relationship between Body Mass Index and epilepsy","volume":"165","author":"Li","year":"2025","journal-title":"Epilepsy Behav"},{"key":"2026051310201148000_jnnp-2025-337861v1.28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046363","article-title":"Association of metabolic disorders and lifestyle behaviors with epilepsy: Evidence from the NHANES database","volume":"104","author":"Tian","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"2026051310201148000_jnnp-2025-337861v1.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306175","article-title":"The relationships between obesity and epilepsy: A systematic review with meta-analysis","volume":"19","author":"Li","year":"2024","journal-title":"PLoS One"},{"key":"2026051310201148000_jnnp-2025-337861v1.30","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00210-025-04561-6","article-title":"Adjuvant potential of metformin with standard anti-seizure medications in persons with active epilepsy: a randomised controlled trial","volume":"399","author":"Sarangi","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026051310201148000_jnnp-2025-337861v1.31","first-page":"923","article-title":"Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026051310201148000_jnnp-2025-337861v1.32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/dmcn.14822","article-title":"Fenfluramine as antiseizure medication for epilepsy","volume":"63","author":"Gogou","year":"2021","journal-title":"Dev Med Child Neurol"},{"key":"2026051310201148000_jnnp-2025-337861v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32500-0"},{"key":"2026051310201148000_jnnp-2025-337861v1.34","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/epi.17737","article-title":"Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo\u2010controlled clinical trial","volume":"64","author":"Sullivan","year":"2023","journal-title":"Epilepsia"},{"key":"2026051310201148000_jnnp-2025-337861v1.35","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026051310201148000_jnnp-2025-337861v1.36","unstructured":"NICE . Fenfluramine for treating seizures associated with Dravet syndrome. TA808. 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ta808\/chapter\/1-Recommendations [Accessed 23 Dec 2025]."},{"key":"2026051310201148000_jnnp-2025-337861v1.37","unstructured":"NICE . Fenfluramine for treating seizures associated with Lennox\u2013Gastaut syndrome in people 2 years and over. TA1050. 2025. Available: https:\/\/www.nice.org.uk\/guidance\/ta1050 [Accessed 23 Dec 2025]."},{"key":"2026051310201148000_jnnp-2025-337861v1.38","unstructured":"NICE . Obesity. 2026. Available: https:\/\/bnf.nice.org.uk\/treatment-summaries\/obesity\/ [Accessed 20 Jan 2026]."},{"key":"2026051310201148000_jnnp-2025-337861v1.39","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1093\/brain\/awae128","article-title":"Morbidity and mortality risks associated with valproate withdrawal in young adults with epilepsy","volume":"147","author":"Mbizvo","year":"2024","journal-title":"Brain (Bacau)"},{"key":"2026051310201148000_jnnp-2025-337861v1.40","unstructured":"TriNetX . Welcome to the world\u2019s largest, living ecosystem of real-world data and evidence for the life sciences and healthcare industries. Global Data, for Global Health. 2023. Available: www.trinetx.com [Accessed 25 Aug 2022]."},{"key":"2026051310201148000_jnnp-2025-337861v1.41","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"2026051310201148000_jnnp-2025-337861v1.42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"2026051310201148000_jnnp-2025-337861v1.43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-63469-0","article-title":"A retrospective cohort study of valproate and infertility in men with epilepsy or bipolar disorder using international health data","volume":"16","author":"Mbizvo","year":"2025","journal-title":"Nat Commun"},{"key":"2026051310201148000_jnnp-2025-337861v1.44","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S002"},{"key":"2026051310201148000_jnnp-2025-337861v1.45","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16547"},{"key":"2026051310201148000_jnnp-2025-337861v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106462"},{"key":"2026051310201148000_jnnp-2025-337861v1.47","unstructured":"TriNetX Engineering . Function propensity_score. Trinetx 010 Functions; 2025. Available: https:\/\/lucid.trinetx.com\/r\/v1.0\/reference\/propensity_score.html [Accessed 18 Jul 2025]."},{"key":"2026051310201148000_jnnp-2025-337861v1.48","unstructured":"TriNetX Engineering . Function propensity_score_matching. Trinetx 010 Functions; 2025. Available: https:\/\/lucid.trinetx.com\/r\/v1.0\/reference\/propensity_score_matching.html#details [Accessed 18 Jul 2025]."},{"key":"2026051310201148000_jnnp-2025-337861v1.49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"2026051310201148000_jnnp-2025-337861v1.50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w"},{"key":"2026051310201148000_jnnp-2025-337861v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.05.021"},{"key":"2026051310201148000_jnnp-2025-337861v1.52","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaa213"},{"key":"2026051310201148000_jnnp-2025-337861v1.53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17437199.2024.2402809","article-title":"How to develop causal directed acyclic graphs for observational health research: a scoping review","volume":"19","author":"Poppe","year":"2025","journal-title":"Health Psychol Rev"},{"key":"2026051310201148000_jnnp-2025-337861v1.54","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/01.ede.0000222409.00878.37","article-title":"Instruments for causal inference: an epidemiologist\u2019s dream?","volume":"17","author":"Hern\u00e1n","year":"2006","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2026051310201148000_jnnp-2025-337861v1.55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-57724-5","article-title":"Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis","volume":"14","author":"Pipek","year":"2024","journal-title":"Sci Rep"},{"key":"2026051310201148000_jnnp-2025-337861v1.56","doi-asserted-by":"publisher","DOI":"10.2307\/2531021"},{"key":"2026051310201148000_jnnp-2025-337861v1.57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.yebeh.2013.05.012","article-title":"Obesity in adults with epilepsy","volume":"28","author":"Janousek","year":"2013","journal-title":"Epilepsy Behav"},{"key":"2026051310201148000_jnnp-2025-337861v1.58","unstructured":"Aprovian C , Aronne L , Sarah B . Clinical management of obesity. 3rd edn. Professional communications, inc, 2025."},{"key":"2026051310201148000_jnnp-2025-337861v1.59","doi-asserted-by":"crossref","first-page":"984824","DOI":"10.3389\/fneur.2022.984824","article-title":"Causal relationship among obesity and body fat distribution and epilepsy subtypes","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Neurol"},{"key":"2026051310201148000_jnnp-2025-337861v1.60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2021.07.019","article-title":"Associations of overweight and obesity with drug-resistant epilepsy","volume":"92","author":"Chen","year":"2021","journal-title":"Seizure"},{"key":"2026051310201148000_jnnp-2025-337861v1.61","doi-asserted-by":"crossref","DOI":"10.5662\/wjm.v14.i1.90590","article-title":"Can propensity score matching replace randomized controlled trials?","volume":"14","author":"Liau","year":"2024","journal-title":"World J Methodol"},{"key":"2026051310201148000_jnnp-2025-337861v1.62","unstructured":"Robins JM . Causal inference: what if. Boca Raton: Taylor and Francis, 2024."},{"key":"2026051310201148000_jnnp-2025-337861v1.63","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"2026051310201148000_jnnp-2025-337861v1.64","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal Structural Models and Causal Inference in Epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2026051310201148000_jnnp-2025-337861v1.65","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000152"},{"key":"2026051310201148000_jnnp-2025-337861v1.66","doi-asserted-by":"crossref","unstructured":"Fernainy P , Godard-Sebillotte C , Lacasse A , et al . Causal mediation analysis: what is it and how can it be used to inform practice and policy. Fam Pract 2025;42. doi:10.1093\/fampra\/cmaf043","DOI":"10.1093\/fampra\/cmaf043"},{"key":"2026051310201148000_jnnp-2025-337861v1.67","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.11.1595"},{"key":"2026051310201148000_jnnp-2025-337861v1.68","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000547","article-title":"Validity of ICD-10-CM codes for determination of diabetes type for persons with youth-onset type 1 and type 2 diabetes","volume":"7","author":"Chi","year":"2019","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-337861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:20:31Z","timestamp":1778692831000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-337861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":68,"alternative-id":["10.1136\/jnnp-2025-337861"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-337861","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}